Methodological standards in non-inferiority AIDS trials: Moving from adherence to compliance

BMC Medical Research Methodology

Volumn 6, Issue , 2006, Pages

  Parienti, Jean Jacques ^a,b,c   Verdon, Renaud ^c   Massari, Véronique ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CHU CÔTE DE NACRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; TREATMENT OUTCOME; VALIDATION STUDY; ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOASSAY; CHI SQUARE DISTRIBUTION; CONFIDENCE INTERVAL; DRUG SCREENING; METHODOLOGY; NONPARAMETRIC TEST; PEER REVIEW; PRACTICE GUIDELINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; THERAPEUTIC EQUIVALENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DRUG EVALUATION; ENDPOINT DETERMINATION; GUIDELINE ADHERENCE; HUMANS; PEER REVIEW, RESEARCH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STATISTICS, NONPARAMETRIC; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 33749536902     PISSN: 14712288     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-6-46     Document Type: Article

References (32)

1. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ: Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Jama 2006, 295:1152-1160.
2. Temple R, Ellenberg SS: Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000, 133:455-463.
3. Djulbegovic B, Clarke M: Scientific and ethical issues in equivalence trials. Jama 2001, 285:1206-1208.
4. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999, 341:1865-1873.
5. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039-2046.
6. Parienti JJ: Tenofovir, equivalence, and noninferiority. Jama 2004, 292:1951; author reply 1951-2.
7. Kirshner B: Methodological standards for assessing therapeutic equivalence. J Clin Epidemiol 1991, 44:839-849.
8. Jones B, Jarvis P, Lewis JA, Ebbutt AF: Trials to assess equivalence: the importance of rigorous methods. Bmj 1996, 313:36-39.
9. McAlister FA, Sackett DL: Active-control equivalence trials and antihypertensive agents. Am J Med 2001, 111:553-558.
10. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W: Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. Jama 2001, 285:1155-1163.
11. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM: Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003, 349:1036-1046.
12. Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fatkenheuer G, D'Arminio-Monforte A, Casiro A, Reiss P, Burger DM, Stek M, Gatell JM: Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. Aids 2003, 17:831-840.
13. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263.
14. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama 2004, 292:191-201.
15. Gathe JCJ, Ive P, Wood R, Schurmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. Aids 2004, 18:1529-1537.
16. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F: A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Aids 2004, 18:2269-2276.
17. DeJesus E, McCarty D, Farthing CF, Shortino DD, Grinsztejn B, Thomas DA, Schrader SR, Castillo SA, Sension MG, Gough K, Madison SJ: Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004, 39:411-418.
18. Molina JM, Journot V, Morand-Joubert L, Yeni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G: Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005, 191:830-839.
19. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004, 39:1038-1046.
20. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M: Comparison of once-daily atazanavir with efavirenz, each in combination with fixeddose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004, 36:1011-1019.
21. Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, Davis EA, Shaefer M: Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:257-264.
22. Sosa N, Hill-Zabala C, Dejesus E, Herrera G, Florance A, Watson M, Vavro C, Shaefer M: Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J Acquir Immune Defic Syndr 2005, 40:422-427.
23. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. Aids 2005, 19:685-694.
24. Moyle GJ, DeJesus E, Cahn P, Castillo SA, Zhao H, Gordon DN, Craig C, Scott TR: Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005, 38:417-425.
25. Telzir European European Public Assessment Report. Scientific discussion http://www.emea.eu.int/humandocs/Humans/EPAR/telzir/telzir.htm.
26. Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martinez E, Miranda J, Munoz-Moreno JA, De la Torre J, Prieto A, Vilades C, Clotet B: Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Syndr 2005, 39:313-316.
27. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251-260.
28. Le Henanff A, Giraudeau B, Baron G, Ravaud P: Quality of reporting of noninferiority and equivalence randomized trials. Jama 2006, 295:1147-1151.
29. Dunnett CW, Gent M: Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics 1977, 33:593-602.
30. Dunnett CW, Gent M: An alternative to the use of two-sided tests in clinical trials. Stat Med 1996, 15:1729-1738.
31. Snapinn SM: Noninferiority trials. Curr Control Trials Cardiovasc med 2000, 1:19-21.
32. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T: The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134:663-694.